Ask AI
OASIS-4
OASIS-4: Phase III Trial of Elinzanetant for Vasomotor Symptoms Associated With Endocrine Therapy in Patients With or at Risk for HR+ Breast Cancer

Released: June 06, 2025

Expiration: December 05, 2025

Activity

Progress
1
Course Completed
Activity Information

Released: June 06, 2025

Expiration: December 05, 2025